RENB 📈 Renovaro Biosciences - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29350E1047
RENB: Cancer, Vaccines, Therapeutics, Diagnostic, Platform, Technology
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California. Web URL: https://renovarobio.com
Additional Sources for RENB Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
RENB Stock Overview
| Market Cap in USD | 146m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2015-02-02 |
RENB Stock Ratings
| Growth 5y | -84.4% |
| Fundamental | - |
| Dividend | - |
| Rel. Strength Industry | -16053 |
| Analysts | - |
| Fair Price Momentum | 0.66 USD |
| Fair Price DCF | - |
RENB Dividends
No Dividends PaidRENB Growth Ratios
| Growth Correlation 3m | 70.3% |
| Growth Correlation 12m | -80% |
| Growth Correlation 5y | -60.2% |
| CAGR 5y | -29.26% |
| CAGR/Mean DD 5y | -0.49 |
| Sharpe Ratio 12m | -0.15 |
| Alpha | -96.84 |
| Beta | 0.78 |
| Volatility | 236.20% |
| Current Volume | 366.8k |
| Average Volume 20d | 1699.6k |
What is the price of RENB stocks?
As of January 01, 2025, the stock is trading at USD 0.84 with a total of 366,776 shares traded.
Over the past week, the price has changed by -18.88%, over one month by +1.89%, over three months by +72.87% and over the past year by -73.81%.
As of January 01, 2025, the stock is trading at USD 0.84 with a total of 366,776 shares traded.
Over the past week, the price has changed by -18.88%, over one month by +1.89%, over three months by +72.87% and over the past year by -73.81%.
Is Renovaro Biosciences a good stock to buy?
No, based on ValueRay Analyses, Renovaro Biosciences (NASDAQ:RENB) is currently (January 2025) a stock to sell. It has a ValueRay Growth Rating of -84.37 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RENB as of January 2025 is 0.66. This means that RENB is currently overvalued and has a potential downside of -21.43%.
No, based on ValueRay Analyses, Renovaro Biosciences (NASDAQ:RENB) is currently (January 2025) a stock to sell. It has a ValueRay Growth Rating of -84.37 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RENB as of January 2025 is 0.66. This means that RENB is currently overvalued and has a potential downside of -21.43%.
Is RENB a buy, sell or hold?
Renovaro Biosciences has no consensus analysts rating.
Renovaro Biosciences has no consensus analysts rating.
What are the forecast for RENB stock price target?
According to ValueRays Forecast Model, RENB Renovaro Biosciences will be worth about 0.7 in January 2026. The stock is currently trading at 0.84. This means that the stock has a potential downside of -13.1%.
According to ValueRays Forecast Model, RENB Renovaro Biosciences will be worth about 0.7 in January 2026. The stock is currently trading at 0.84. This means that the stock has a potential downside of -13.1%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 0.7 | -13.1% |